MedPath

IPSEN, OOO

🇫🇷France
Ownership
-
Established
1929-01-01
Employees
5.7K
Market Cap
$9.8B
Website
https://www.ipsen.com/

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Phase 3
Completed
Conditions
Digestive Fistulae
Interventions
First Posted Date
2008-08-07
Last Posted Date
2019-03-04
Lead Sponsor
Ipsen
Target Recruit Count
111
Registration Number
NCT00729313
Locations
🇫🇷

Hôpital Nord, Marseille, France

🇫🇷

CHU J. Minjoz, Besançon, France

🇫🇷

Groupe Hospitalier Pitié-Salpêtrière, Paris, France

and more 15 locations

Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)

Completed
Conditions
Idiopathic Short Stature
First Posted Date
2008-07-04
Last Posted Date
2019-01-15
Lead Sponsor
Ipsen
Target Recruit Count
275
Registration Number
NCT00710307
Locations
🇫🇷

Ipsen Central Contact, Paris, France

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

Phase 4
Completed
Conditions
Acromegaly
Interventions
First Posted Date
2008-06-19
Last Posted Date
2019-01-29
Lead Sponsor
Ipsen
Target Recruit Count
124
Registration Number
NCT00701363
Locations
🇷🇴

University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania

🇬🇷

Polykliniki Hospital - Department of Endocrinology, Athens, Greece

🇬🇷

B IKA Panagia Hospital - Department of Endocrinology, Thessaloniki, Greece

and more 41 locations

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

Phase 3
Completed
Conditions
Acromegaly
Interventions
First Posted Date
2008-06-05
Last Posted Date
2022-10-14
Lead Sponsor
Ipsen
Target Recruit Count
108
Registration Number
NCT00690898
Locations
🇨🇿

Všeobecná fakultní nemocnice, Karlova Univerzita, Praha, Czechia

🇫🇮

The Turku University Central Hospital, Turku, Finland

🇫🇷

Hopital De Bois Guillaume, Bois-Guillaume, France

and more 24 locations

Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

Completed
Conditions
Acromegaly
First Posted Date
2008-05-29
Last Posted Date
2019-01-11
Lead Sponsor
Ipsen
Target Recruit Count
260
Registration Number
NCT00686348
Locations
🇺🇸

Ipsen, Basking Ridge, New Jersey, United States

Somatuline Autogel Preference and Health Economy Study

Phase 4
Completed
Conditions
Neuroendocrine Tumour With Carcinoid Symptoms
First Posted Date
2008-05-21
Last Posted Date
2019-11-22
Lead Sponsor
Ipsen
Target Recruit Count
26
Registration Number
NCT00681187
Locations
🇳🇴

Haukeland University Hospital / Kreftafd, Bergen, Norway

🇳🇴

University Hospital North-Norway / GastroLab, Tromsø, Norway

🇳🇴

S:t Olavs Hospital / Medisinsk Afd, Trondheim, Norway

and more 7 locations

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Phase 2
Terminated
Conditions
Overactive Bladder
Interventions
Biological: Botulinum toxin type A
Drug: Placebo
First Posted Date
2007-12-20
Last Posted Date
2019-11-22
Lead Sponsor
Ipsen
Target Recruit Count
81
Registration Number
NCT00578097
Locations
🇧🇪

UZ Gasthuisberg, Leuven, Belgium

🇨🇿

Urologická klinika, Olomouc, Czechia

🇫🇷

Hôpital Michallon - CHU de Grenoble, Grenoble Cedex, France

and more 28 locations

Long-Term Treatment With rhIGF-1 in GHIS

Phase 2
Completed
Conditions
Growth Hormone Insensitivity Syndrome
Interventions
First Posted Date
2007-12-12
Last Posted Date
2023-07-06
Lead Sponsor
Ipsen
Target Recruit Count
92
Registration Number
NCT00571727
Locations
🇺🇸

Ipsen, Brisbane, California, United States

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

First Posted Date
2007-12-12
Last Posted Date
2023-03-30
Lead Sponsor
Ipsen
Target Recruit Count
106
Registration Number
NCT00572156
Locations
🇺🇸

Ipsen, Brisbane, California, United States

Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty

Phase 3
Completed
Conditions
Precocious Puberty
Interventions
First Posted Date
2007-11-28
Last Posted Date
2022-10-12
Lead Sponsor
Ipsen
Target Recruit Count
37
Registration Number
NCT00564850
Locations
🇫🇷

Hôpital Hotel-Dieu (CHU), Angers, France

🇫🇷

Hôpital Saint-Jacques, Besancon, France

🇫🇷

Medical Centre, Bordeaux, France

and more 15 locations
© Copyright 2025. All Rights Reserved by MedPath